Educational Programmes
E-learning: Current opinions on managing nmCRPC and the implications of new imaging modalities
Our faculty of international experts, Prof. Alexander Drzezga (Germany), Assoc. Prof. Alicia Morgans (USA) and Prof. David Pfister (Germany) discuss the current opinions on managing nmCRPC and the implications of new imaging modalities.
read more
Current opinions on managing nmCRPC and the implications of new imaging modalities
We recently delivered a virtual Experts Knowledge Share meeting discussing the Current opinions on managing nmCRPC and the implications of new imaging modalities.
read more Highlights of 2020 in prostate, urothelial and kidney cancer
Dr Ray Manneh Kopp takes a look at the highlights of 2020 from GU CONNECT, in particular the new trials and practice changing developments in prostate, urothelial and kidney cancer, as well as the impact of COVID-19 on existing treatments and protocols.
read more GU CONNECT Prostate Cancer Management Masterclass: plenary session recordings (videos and slides)
Assoc. Prof. Alicia Morgans MD, MPH summarises the recent interactive Prostate Cancer Management Masterclass that she co-hosted, along with Dr. Neal Shore, MD, FACS, Assoc. Prof. Tanya Dorff, MD and Prof. Evan Yu, MD
read more The SHARE Communication Framework for mCRPC: video, slides and e-learning
GU CONNECT has developed an accredited interactive e-learning, slide set and short informative videos to help you confidently and quickly apply the SHARE Communication Framework and move towards even better patient conversations.
read more E-Learning: Treatment sequencing for mCRPC patients within the changing landscape of mHSPC
As a result of the success of the Experts Knowledge Share meeting during ESMO 2019, GU CONNECT has turned the educational programme into an interactive e-learning. Watch the video and then take the e-learning for your CME credit.
read more Advanced PET Imaging in Prostate Cancer
Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer.
read more Adjuvant Therapy in mRCC
This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC.
read more Immunotherapy in genitourinary tumors
This month Prof. Sandy Srinivas and Prof. David Pfister provide an interesting overview of Immunotherapy in genitourinary tumors.
read more
GU CONNECT Update from ESMO 2020
GU CONNECT has summarised the highlights from ESMO 2020 for you
read more GU CONNECT Update from ASCO 2020
GU CONNECT has summarised the highlights from ASCO for you.
read more GU CONNECT Update from ASCO GU 2020
GU CONNECT has summarised highlights of the recent ASCO GU 2020 meeting for you.
read more GU CONNECT Update from ESMO 2019
GU CONNECT has summarised highlights of the recent ESMO 2019 meeting for you.
read more GU CONNECT Update from ASCO 2019
GU CONNECT has summarised the highlights from ASCO 2019 for you
read more Update from ASCO GU 2019
GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.
read more GU CONNECT Update from ESMO 2018
GU CONNECT has summarised the highlights from ESMO 2018 for you.
read more Update from San Francisco 2018
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
read more A CONNECT Update from Madrid
GU CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.
read more GU CONNECT update from Orlando
GU CONNECT has summarised the highlights of the recent congress of the American Society of Clinical Oncology GU (ASCO GU) 2017 in Orlando, USA for you.
read morePlease submit your clinical topic for the next GU CONNECT newsletter here.
Maintenance therapy for metastatic urothelial cancer
GU CONNECT expert, Prof. Sandy Srinivas, MD discusses maintenance therapy for metastatic urothelial cancer, and in particular the practice changing clinical trial JAVELIN 100.
read more Clinical review of nmCRPC: Key trials and endpoints
Prof. Steven Joniau, MD, PhD provides an overview of nmCRPC and highlights of the SPARTAN, PROSPER and ARAMIS trials including the recent overall survival update and discusses the safety and quality of life data.
read more The role and place of genetic testing in prostate cancer
Our GU CONNECT experts, Dr Daniel Keizman (Israel), Prof Gert Attard (UK), Dr Neal Shore (USA), Dr Elena Castro (Spain) and Dr Roberto Iacovelli (Italy) provide their thoughts and opinions on the challenging topic of the role and place of genetic testing in prostate cancer.
read more
Optimal bone health management strategies in patients with prostate cancer
Dr. Daniel Keizman discusses the strategies for optimal bone health management in patients with prostate cancer.
read more Antibody-drug conjugates in urothelial cancer
Prof. Sandy Srinivas, Stanford University Medical Center, California, USA, takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.
read more Treating mCRPC patients who have progressed on AR-directed therapy
Dr. Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
read more Treatment sequencing in metastatic renal cell carcinoma (mRCC)
Dr. Roberto Iacovelli brings to you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.
read more New therapies for metastatic hormone sensitive prostate cancer
As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.
read more Treating Oligometastatic Prostate Cancer
Assoc. Prof. Tanya B. Dorff looks into the use of imaging along with the treatment of oligometastatic prostate cancer.
read more Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)
Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.
read more
